ArticleDiagnostics (Basel, Switzerland)2022
miR-145, miR-92a and miR-375 Show Differential Expression in Serum from Patients with Diabetic Retinopathies.
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.International journal of molecular sciences · 2024Trial
- Identification of serum miR‑320a in gestational diabetes mellitus for predicting macrosomia and in vitro mechanistic investigation.BMC medical genomics · 2026Article
- miR-4687-5p promotes the progression of diabetic retinopathy by targeting SIRT2 to mediate inflammatory responses.Diabetology & metabolic syndrome · 2026Article
- Clinical value of high-frequency ultrasound and serum miR-92a-3p in diabetic peripheral neuropathy.Journal of diabetes investigation · 2025Article
- Characterizing Circulating microRNA Signatures of Type 2 Diabetes Subtypes.International journal of molecular sciences · 2025Article
- Use of serum long non-coding RNA expression panel as a marker for diabetic retinopathy.Frontiers in cardiovascular medicine · 2025Article
- Correlation analysis of serum miRNA expression levels with the degree of macular edema in patients with retinal vein occlusion and its clinical implications.Frontiers in neurology · 2025Article
- miR-92a and integrin expression in fibrovascular membranes in proliferative diabetic retinopathy.Frontiers in ophthalmology · 2023Article
- Article
- Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: Recent progress and future perspectives.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Diabetic retinopathies are important disabling conditions. Micro-RNAs (miRNAs) are regulators of gene expression and diseases can change their expression. Our aim was to analyze the expression of miRNAs in serum and vitreous samples from patients with diabetic retinopathies. The following groups and number of individuals were included: proliferative diabetic retinopathy (PDR) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.